Loading stock data…
Parabilis Medicines, Inc. (PBLS)
$39.77-0.65 (-1.61%)
Market ClosedLast close Sep 8
Parabilis Medicines, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$47.45M↓ | -$40.24M |
| Net Income | -$45.32M↓ | -$38.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery plat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.25%
Volume
Today's trading volume
563,961
Recent News
Young startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
Why Parabilis Medicines Stock Is On Investors’ Radar Parabilis Medicines (PBLS) has recently drawn fresh attention after a sharp single day move, with the stock closing at $27.26 and down around 10% over that session. For investors tracking this clinical stage biopharmaceutical company, the move highlights how sentiment can quickly shift around pre revenue drug developers that are still reporting losses, in this case a net loss of $209.706 million and no reported revenue. See our latest...
How to Play PBLS Stock After the Parabilis IPO
Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.